Teva Pharmaceutical Industries Ltd Stock Rating Lowered by Wells Fargo (TEVA)
Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) was downgraded by investment analysts at Wells Fargo from an “outperform” rating to a “market perform” rating in a note issued to investors on Monday, TheFlyOnTheWall.com reports.
Shares of Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) opened at 40.82 on Monday. Teva Pharmaceutical Industries Ltd has a one year low of $36.63 and a one year high of $46.38. The stock’s 50-day moving average is currently $38.50. The company has a market cap of $34.983 billion and a P/E ratio of 18.14.
Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) last released its earnings data on Thursday, February 7th. The company reported $1.32 earnings per share for the quarter, missing the analysts’ consensus estimate of $1.33 by $0.01. The company had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.26 billion. During the same quarter last year, the company posted $1.59 earnings per share. Teva Pharmaceutical Industries Ltd’s revenue was down 7.5% compared to the same quarter last year. Analysts expect that Teva Pharmaceutical Industries Ltd will post $5.07 EPS for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at TheStreet reiterated a “hold” rating on shares of Teva Pharmaceutical Industries Ltd in a research note to investors on Thursday, March 7th. Separately, analysts at Argus downgraded shares of Teva Pharmaceutical Industries Ltd from a “buy” rating to a “hold” rating in a research note to investors on Monday, February 25th. They now have a $48.00 price target on the stock.
Ten equities research analysts have rated the stock with a buy rating, one has issued an overweight rating, and sixteen have assigned a hold rating to the company. The company presently has a consensus rating of “overweight” and a consensus price target of $45.11.
Teva Pharmaceutical Industries Ltd (Teva) is a global pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.